Watch this great video with Dr Minh Tran discussing his experiencing using the SAFIRA™ in practice. Medovate talked with Dr Minh T. Tran after he had successfully used SAFIRA™ with a number of patients undergoing regional anaesthesia. Watch here: https://bit.ly/2REHUbo Dr Tran is based in Sydney and it was great to hear his positive feedback on his experience of using the device for upper limb blocks, as well as hip and knee surgeries. Watch the short video to hear Dr Tran's thoughts on the autonomy SAFIRA™ gives anaesthetists, as well as the consistency of injection pressure. As the Australian and New Zealand distributor for SAFIRA™, LTR Medical are available to help any regional anaesthetists who would like to see the benefits of this exciting technology for themselves. For further information, call 1800 319 419 or visit our product page SAFIRA™ SAFIRA™: SAFer Injection for Regional Anaesthesia Creates a single operator procedure Engineered [...]
Another satisfied Anaesthetist evaluating the SAFIRA – SAFer Injection for Regional Anaesthesia. Providing safer and easier Regional Anaesthesia. For more information call us on 1800 319 419 or visit our product page SAFIRA™
LTR Medical is pleased to announce that CitraFlow™ Prefilled Syringes have gained TGA approval. CitraFlow™ 4%, 30% and 46.7% prefilled syringes are a proven alternative to heparin for flushing and locking catheters/ports on patients. Sodium citrate avoids the risks associated with systemic heparinisation and is safe for use in patients with suspected or confirmed Heparin Induced Thrombocytopenia. Clinical studies have shown that the use of ananticoagulant Sodium Citrate solution to lock central venous catheters has significant advantages compared to existing standards of care. CitraFlow™ is highly effective in maintaining catheter patency, works as an anticoagulant and decreases the incidence of infection. CitraFlow™ is designed for use in a sterile field. For more information, visit our product page MedXL - LTR Medical or call us on 1800 319 419
LTR Medical is proud to announce that with TGA approval we will move to the next stage in launching the SAFIRA™ - SAFer Injection for Regional Anaesthesia in the Australian and New Zealand markets. Manufactured by Medovate, the SAFIRA™ gives Anaesthetists control over regional anaesthesia blocks by making it a single operator procedure. With an engineered safety solution to control injection pressure threshold, it reduces the change of nerve injury. LTR Medical CEO Lee Rodne commented: “The team at LTR Medical are excited to introduce the SAFIRA® to the Australian and New Zealand Markets. This groundbreaking new technology gives Anaesthetists greater control when placing nerve blocks and reduces the chance of nerve damage, improving patient outcomes.” For further information, visit our product page or call us on 1800 319 419.
LTR Medical is excited to launch the CA-500 Ambulatory Syringe Pump in the Australian and New Zealand markets. The CA-500 is a portable, intuitive syringe pump ideal for delivery of medications and fluids in small volume and low rate. With a comprehensive range of features, the pump is suitable for infusion therapy across a wide variety of applications in inpatient, outpatient and home care environments. For further information, please visit our product page – CA-500 Ambulatory Syringe Pump – or call us on 1800 319 419. #infusion #HITH #palliativecare #patientsafety
LTR Medical has concluded a distribution agreement with Medovate, the medical device development company which will provide exclusivity for SAFIRA® (SAFer Injection for Regional Anaesthesia) in Australia and New Zealand. Developed in collaboration with anaesthetists in the UK National Health Service (NHS), SAFIRA® is set to help revolutionise standard regional anaesthesia clinical practice. With the use of regional anaesthesia continuing to grow significantly in Australia and New Zealand, SAFIRA® has the potential to make a significant impact. Amid the current COVID-19 pandemic, recent publications have recommended regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because regional anaesthesia preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19 compared to general anaesthesia. Already launched across the United States, this distribution agreement to bring SAFIRA® to market in Australia and New Zealand marks a significant further step in making this [...]